Choroideremia B
: O
close O
linkage O
to O
DXYS1 O
and O
DXYS12 O
demonstrated O
by O
segregation O
analysis O
and O
historical O
- O
genealogical O
evidence O
. O

The O
clinical O
features O
of O
eight O
cases O
with O
15q11 O
- O
12 O
deletion O
were O
very O
similar O
to O
those O
originally O
described O
in O
PWS B
. O

There O
were O
59 O
deaths O
from O
malignant B
neoplasms I
in O
relatives O
dying O
before O
age O
75 O
, O
compared O
to O
42 O
. O

Mutation O
and O
haplotype O
studies O
of O
familial B
Mediterranean I
fever I
reveal O
new O
ancestral O
relationships O
and O
evidence O
for O
a O
high O
carrier O
frequency O
with O
reduced O
penetrance O
in O
the O
Ashkenazi O
Jewish O
population O
. O

To O
compare O
somatic O
and O
germline O
mutations O
, O
we O
used O
the O
VHL B
database O
, O
which O
includes O
507 O
mutations O
. O

We O
report O
that O
heterozygosity O
for O
a O
targeted O
murine O
Wt1 O
allele O
, O
Wt1 O
( O
tmT396 O
) O
, O
which O
truncates O
ZF3 O
at O
codon O
396 O
, O
induces O
mesangial B
sclerosis I
characteristic O
of O
DDS B
in O
adult O
heterozygous O
and O
chimeric O
mice O
. O

Argininemia B
is O
a O
rare O
autossomal B
recessive I
disorder I
caused O
by O
deficiency B
in I
the I
cytosolic I
liver I
- I
type I
arginase I
enzyme I
( O
L O
- O
arginine O
urea O
- O
hydrolase O
; O
E O
. O
C O
. O
3 O
. O
5 O
. O
3 O
. O
1 O
) O
. O

Deficiency B
of I
glucose I
- I
6 I
- I
phosphate I
dehydrogenase I
( O
G6PD O
) O
is O
usually O
found O
at O
high O
frequencies O
in O
areas O
of O
the O
world O
where O
malaria B
has O
been O
endemic O
. O

The O
rare O
form O
of O
the O
Q356R O
polymorphism O
was O
significantly O
( O
P O
= O
0 O
. O
03 O
) O
associated O
with O
a O
family O
history O
of O
ovarian B
cancer I
, O
suggesting O
that O
this O
polymorphism O
may O
influence O
ovarian B
cancer I
risk O
. O

We O
evaluated O
the O
hypothesis O
that O
Huntington B
disease I
( O
HD B
) O
is O
influenced O
by O
the O
normal O
HD B
allele O
by O
comparing O
transmission O
patterns O
of O
genetically O
linked O
markers O
at O
the O
D4S10 O
locus O
in O
the O
normal O
parent O
against O
age O
at O
onset O
in O
the O
affected O
offspring O
. O

Decrease O
in O
GTP O
cyclohydrolase O
I O
gene O
expression O
caused O
by O
inactivation O
of O
one O
allele O
in O
hereditary B
progressive I
dystonia I
with O
marked O
diurnal O
fluctuation O
. O

Moreover O
, O
MAGEL2 O
/ O
Magel2 O
are O
expressed O
only O
from O
the O
paternal O
allele O
in O
brain O
, O
suggesting O
a O
potential O
role O
in O
the O
aetiology O
of O
PWS B
and O
its O
mouse O
model O
, O
respectively O
. O
. O

These O
data O
demonstrate O
that O
ATM O
and O
the O
hMre11 O
/ O
hRad50 O
/ O
Nbs1 O
protein O
complex O
act O
in O
the O
same O
DNA O
damage O
response O
pathway O
and O
link O
hMre11 O
to O
the O
complex O
pathology O
of O
A B
- I
T I
. O
. O

Our O
data O
support O
the O
hypothesis O
that O
DM B
is O
a O
contiguous O
gene O
syndrome O
associated O
with O
the O
partial O
loss O
of O
both O
DMPK O
and O
SIX5 O
. O
. O

Abnormalities O
of O
chromosome O
region O
15q11 O
- O
13 O
are O
associated O
with O
Angelman B
syndrome I
( O
AS B
) O
and O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
. O

Most O
VCFS B
/ O
DGS B
patients O
have O
a O
similar O
3 O
Mb O
deletion O
, O
some O
have O
a O
nested O
distal O
deletion O
breakpoint O
resulting O
in O
a O
1 O
. O

This O
percentage O
of O
CTNNB1 O
mutations O
is O
greater O
than O
in O
all O
other O
human O
tumours B
examined O
thus O
far O
, O
and O
directly O
implicates O
beta O
- O
catenin O
/ O
LEF O
misregulation O
as O
the O
major O
cause O
of O
hair O
matrix O
cell O
tumorigenesis O
in O
humans O
. O
. O

Pelizaeus B
- I
Merzbacher I
disease I
: O
detection O
of O
mutations O
Thr181 O
- O
- O
- O
- O
Pro O
and O
Leu223 O
- O
- O
- O
- O
Pro O
in O
the O
proteolipid O
protein O
gene O
, O
and O
prenatal O
diagnosis O
. O

Additionally O
, O
a O
second O
previously O
identified O
recurrent O
muta O
tion O
, O
C2272T O
, O
in O
exon O
16 O
has O
been O
discovered O
in O
a O
patient O
with O
FHM B
. O
. O

Phenylketonuria B
( O
PKU B
) O
is O
a O
metabolic B
disease I
caused O
by O
recessive O
mutations O
of O
the O
gene O
encoding O
the O
hepatic O
enzyme O
phenylalanine O
hydroxylase O
( O
PAH O
) O
. O

We O
analyzed O
the O
HEXA O
gene O
of O
one O
pseudodeficient O
subject O
and O
identified O
both O
a O
C739 O
- O
to O
- O
T O
substitution O
that O
changes O
Arg247 O
- O
- O
- O
- O
Trp O
on O
one O
allele O
and O
a O
previously O
identified O
Tay B
- I
Sachs I
disease I
mutation O
on O
the O
second O
allele O
. O

Novel O
mutations O
in O
the O
Wiskott B
- I
Aldrich I
syndrome I
protein O
gene O
and O
their O
effects O
on O
transcriptional O
, O
translational O
, O
and O
clinical O
phenotypes O
. O

We O
describe O
an O
11 O
- O
year O
- O
old O
girl O
suffering O
from O
recurrent B
meningitis I
with O
a O
complete O
absence B
of I
the I
seventh I
component I
of I
complement I
( O
C7 O
) O
. O

For O
genetic O
counseling O
and O
predictive O
testing O
in O
families O
with O
inherited B
breast I
- I
ovarian I
cancer I
, O
penetrances O
and O
expressions O
of O
the O
underlying O
mutations O
should O
be O
known O
. O

Inherited B
complement I
deficiencies I
are O
associated O
with O
a O
variety O
of O
connective O
tissue O
diseases O
. O

More O
than O
75 O
% O
of O
the O
reported O
mutations O
in O
the O
hereditary B
breast I
and I
ovarian I
cancer I
gene O
, O
BRCA1 O
, O
result O
in O
truncated O
proteins O
. O

Of O
the O
15 O
families O
that O
contain O
cases O
of O
ovarian B
cancer I
, O
94 O
% O
were O
estimated O
to O
be O
linked O
to O
BRCA1 O
. O

In O
order O
to O
demonstrate O
the O
effect O
of O
prophylactic O
colchicine O
treatment O
on O
the O
natural O
history O
of O
familial B
Mediterranean I
fever I
( O
FMF B
) O
, O
a O
family O
is O
presented O
with O
6 O
out O
of O
9 O
siblings O
affected O
by O
FMF B
. O

The O
unambiguous O
identification O
of O
a O
crossover O
event O
within O
hemochromatosis B
families O
is O
very O
difficult O
; O
it O
is O
particularly O
hampered O
by O
the O
variability O
of O
the O
phenotypic O
expression O
as O
well O
as O
by O
the O
sex O
- O
and O
age O
- O
related O
penetrance O
of O
the O
disease O
. O

Thus O
, O
people O
with O
ALD B
and O
AMN B
may O
have O
subclinical O
partial O
adrenocrotical B
insufficiency I
. O

The O
genetic B
defect I
in O
DM B
is O
a O
CTG O
repeat O
expansion O
located O
in O
the O
3 O
untranslated O
region O
of O
DMPK O
and O
5 O
of O
a O
homeodomain O
- O
encoding O
gene O
, O
SIX5 O
( O
formerly O
DMAHP O
; O
refs O
2 O
- O
5 O
) O
. O

